A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2018
At a glance
- Drugs E 2027 (Primary)
- Indications Dementia; Lewy body disease
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 18 Jul 2018 According to an Eisai Inc media release, results will be presented at Alzheimer's Association International Conference (AAIC) 2018.
- 05 Jun 2018 Status changed from not yet recruiting to recruiting.
- 19 Mar 2018 New trial record